Esperion Therapeutics Q3 EPS $(0.37) Beats $(0.43) Estimate, Sales $33.96M Beat $29.58M Estimate
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics reported Q3 earnings per share (EPS) of $(0.37), beating the analyst consensus estimate of $(0.43) by 13.95%. This is a 54.32% increase over losses from the same period last year. The company also reported quarterly sales of $33.96 million, beating the analyst consensus estimate of $29.58 million by 14.81%. This is a 78.93% increase over sales from the same period last year.
November 07, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion Therapeutics reported better than expected Q3 earnings and sales, which could positively impact the stock price.
Esperion Therapeutics reported Q3 earnings and sales that beat analyst estimates. This is generally seen as positive news and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100